Search - tctmd.com

Displaying 181 - 200 of 288

Sort: Relevancy | Date

Certain CAD Subgroups Without Severe HF Face Heightened Risk of Sudden Cardiac Death

News Daily News

Certain CAD Subgroups Without Severe HF Face Heightened Risk of Sudden Cardiac Death

May 02, 2018

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

Podcast TCTMD Talking Points

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

May 02, 2018

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

News Conference News SCAI 2018

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

May 01, 2018

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

TCTMD’s Top 10 Most Popular Stories for April 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

April 30, 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

April 27, 2018

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

News Conference News SCAI 2018

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

April 26, 2018

Top Stories in Cardiology: April 2018

Podcast Heart Sounds

Top Stories in Cardiology: April 2018

April 25, 2018

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

April 24, 2018

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

News Daily News

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

Yael L. Maxwell

April 23, 2018

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

News Daily News

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

April 19, 2018

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

April 18, 2018

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock

Podcast TCTMD Talking Points

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock

April 18, 2018

iFR Pullback Provides Roadmap for CAD Severity, Predicts Hemodynamics Post-PCI

News Daily News

iFR Pullback Provides Roadmap for CAD Severity, Predicts Hemodynamics Post-PCI

April 17, 2018

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

Presentation

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

April 17, 2018

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

News Daily News

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Michael O'Riordan

April 16, 2018

$Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina$

News Daily News

Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina

April 16, 2018

Abciximab in ‘Short Supply’ Worldwide

News Daily News

Abciximab in ‘Short Supply’ Worldwide

April 13, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.